Plain-language: Dirlotapide (Slentrol), the dog weight-loss drug — withdrawn in the EU, still on the US record (EN+ZH)

EN — For dog owners. Dirlotapide is the active ingredient in Slentrol (dirlotapide) — EMEA/V/C/000116, a canine weight-loss medicine whose indication was As an aid in the management of overweight and obesity in adult dogs. In the EU its status is now Status: Withdrawn. But in the US FDA adverse-event database the molecule still shows Dirlotapide: 2994 reports, with top reported reactions including Vomiting 927. Two cautions: the counts are CUMULATIVE as of openFDA pull 2026-07-22, and "Lack of efficacy" terms denote product-performance reports, not adverse reactions. Most important: reported ≠ causal — a report does not prove the drug caused the event. Bottom line — the drug is off the EU market; its US report file stays on the books.

中文 — 给养狗主人。 Dirlotapide 是犬用减肥药 Slentrol (dirlotapide) — EMEA/V/C/000116 的有效成分，适应症为帮助管理成年犬超重与肥胖（原文：As an aid in the management of overweight and obesity in adult dogs）。它在欧盟的状态是 Status: Withdrawn（已撤市）。但在美国 FDA 不良事件数据库里仍有 Dirlotapide: 2994 条报告，最多报告的反应含 Vomiting 927（呕吐 927 例）。两点注意：计数是 CUMULATIVE as of openFDA pull 2026-07-22（累计快照）；且"缺乏疗效"类术语是产品性能报告，不是不良反应（"Lack of efficacy" terms denote product-performance reports, not adverse reactions）。最重要：reported ≠ causal（有报告 ≠ 有因果）。结论——药已在欧盟撤市，但美国的报告档案仍在。

Source article: dirlotapide-withdrawal-ade (built from C1-verified openFDA / EMA source topics).

Claims (verified as substrings of the C1-verified source article)

• Slentrol (dirlotapide) — EMEA/V/C/000116
• As an aid in the management of overweight and obesity in adult dogs
• Status: Withdrawn
• Dirlotapide: 2994
• Vomiting 927
• CUMULATIVE as of openFDA pull 2026-07-22
• "Lack of efficacy" terms denote product-performance reports, not adverse reactions
• reported ≠ causal